50424-96-9

Basic information

• Product Name: Benzoyl chloride, 4-methoxy-2-nitro-
• CAS NO: 50424-96-9
• Molecular Formula: C8H6ClNO4
• Molecular Weight: 215.593
• Mol File: 50424-96-9.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 4-methoxy-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 4-methoxy-2-nitro-(50424-96-9)
• EPA Substance Registry System: Benzoyl chloride, 4-methoxy-2-nitro-(50424-96-9)

Safety Data

• Hazardous Substances Data: 50424-96-9(Hazardous Substances Data)

Upstream product

• 33844-21-2 2-nitro-4-methoxybenzoic acid 

Downstream Products

• 27037-34-9 7-methoxyquinoline-2,4-diol 
• 1219081-05-6 N-(4-cyano-phenyl)-4-methoxy-2-nitro-benzamide 
• 1017929-17-7 C₁₄H₂₀N₂O₄ 
• 1199793-59-3 (+/-)-2-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-4-methoxybenzamide 
• 1609643-59-5 5-(4-methoxy-2-nitrophenyl)-3-phenyl-1,2,4-oxadiazole 
• 1422357-92-3 C₂₃H₂₁N₃O₆ 
• 1422357-86-5 2-amino-N-[4-(2-hydroxyethyl)phenyl]-4-methoxybenzamide 
• 1422357-80-9 N-[4-(2-hydroxyethyl)phenyl]-4-methoxy-2-nitrobenzamide 
• 1352126-84-1 2-[4-methoxy-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid 
• 33844-22-3 4-methoxy-2-nitro-benzoic acid amide 
• 1199793-62-8 (+/-)-N-(1-azabicyclo[2.2.2]oct-3-yl)-4-methoxy-2-nitrobenzamide 
• 941606-42-4 N-(4-chloro-phenyl)-4-methoxy-2-nitro-benzamide 

Relevant articles and documents

Anthranilic acid derivatives as nuclear receptor modulators - Development of novel PPAR selective and dual PPAR/FXR ligands

Nuclear receptors, especially the peroxisome proliferator activated receptors (PPARs) and the farnesoid X receptor (FXR) fulfill crucial roles in metabolic balance. Their activation offers valuable therapeutic potential which has high clinical relevance w

Synthesis and Quantitative Structure-Activity Relationships of Selective BCRP Inhibitors

The breast cancer resistance protein (BCRP/ABCG2) is a member of the ABC transporter superfamily. This protein has a number of physiological functions, including protection of the human body from xenobiotics. The overexpression of BCRP in certain tumor cell lines causes cross-resistance against various drugs used in chemotherapeutic treatment. In a previous work we showed that a new class of compounds derived from XR9576 (tariquidar) selectively inhibits BCRP. In this work we synthesized more members of this class, with modification on the second and third aromatic rings. The inhibitory activities against BCRP and P-gp were assayed using a Hoechst 33342 assay for BCRP and a calcein AM assay for P-gp. Finally, quantitative structure-activity relationships for both aromatic rings were established. The results obtained show the importance of the electron density on the third aromatic ring, influenced by substituents, pointing to interactions with aromatic residues of the protein binding site. In the second aromatic ring the activity of compounds is influenced by the steric volume of the substituents.

Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: Exploration of P2 quinazoline substituents

Novel NS3/4A protease inhibitors comprising quinazoline derivatives as P2 substituent were synthesized. High potency inhibitors displaying advantageous PK properties have been obtained through the optimization of quinazoline P2 substituents in three series exhibiting macrocyclic P2 cyclopentane dicarboxylic acid and P2 proline urea motifs. For the quinazoline moiety it was found that 8-methyl substitution in the P2 cyclopentane dicarboxylic acid series improved on the metabolic stability in human liver microsomes. By comparison, the proline urea series displayed advantageous Caco-2 permeability over the cyclopentane series. Pharmacokinetic properties in vivo were assessed in rat on selected compounds, where excellent exposure and liver-to-plasma ratios were demonstrated for a member of the 14-membered quinazoline substituted P2 proline urea series.